Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1499-1506

  Sun, Wei ^a   Chen, Yinghui ^b   Yuan, Weien ^c  

^a JILIN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

5 fluorouracil; Absorbable gelatin sponge; Sustained release; Tumor

Indexed keywords

ACETIC ACID ETHYL ESTER; FLUOROURACIL; POLYGLACTIN;

ABSORPTION; ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; DRUG TUMOR LEVEL; ENCAPSULATION; HEMOSTATIC ABSORBABLE GELATIN SPONGE; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL DEVICE; MOUSE; NEOPLASM; NONHUMAN; PHARMACOKINETICS; QUALITY OF LIFE; RAT; REPRODUCIBILITY; SUSPENSION; SYSTEMIC DISEASE;

5-FLUOROURACIL; ABSORBABLE GELATIN SPONGE; SUSTAINED-RELEASE; TUMOR;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DELAYED-ACTION PREPARATIONS; FLUOROURACIL; GELATIN SPONGE, ABSORBABLE; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; NEOPLASM RECURRENCE, LOCAL; POLYGLYCOLIC ACID; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84876501234     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41462     Document Type: Article

References (41)

1. Günzburg WH, Löhr M, Salmons B. Novel treatments and therapies in development for pancreatic cancer. Expert Opin Invest Drugs. 2002;11:769-786.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-1057.
3. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res. 2005;165:250-259.
4. Segura C, Afchain P, de Gramont A, André T. Adjuvant treatment of colorectal cancer. Bull Du Cancer. 2006;93:683-690.
5. El-Khoueiry AB, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006;24:50-55.
6. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24:3347-3353.
7. Jorizzo J. Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy? J Drug Dermatol. 2004;3:21-25.
8. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209-214.
9. Yarde Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol. 2004;31:6-13.
10. Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophos-phamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005;23:8313-8321.
11. Eniu A, Carlson RW, Aziz Z, et al. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 2006;12: S38-S53.
12. Roüessé J, de la Lande, B, Bertheault-Cvitkovic F, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006;64:1072-1080.
13. Roullin VG, Mege M, Lemaire L, et al. Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization. Pharm Res. 2004;21:1558-1563.
14. Larina IV, Evers BM, Ashitkov TV, et al. Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation. Technol Cancer Res Treat. 2005;4:217-226.
15. Muvaffak A, Gurhan I, Gunduz U, Hasirci N. Preparation and characterization of a biodegradable drug targeting system for anticancer drug delivery: microsphere-antibody conjugate. J Drug Target. 2005;13: 151-159.
16. Santhi K, Dhanaraj SA, Vinod J, et al. A study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil. Drug Dev Ind Pharm. 2002;28:1171-1179.
17. Fournier E, Passirani C, Vonarbourg A, et al. Therapeutic efficacy of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm. 2003;268:31-35.
18. Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil releasing microspheres in malignant glioma. A phase I study. Cancer. 2004;100:405-410.
19. Blanco MD, Garcia O, Gomez C, et al. In-vivo drug delivery of 5-fluorouracil using poly(2-hydroxyethyl methacrylate-coacrylamide) hydrogels. J Pharm Pharmacol. 2000;52:1319-1325.
20. Zambito Y, Baggiani A, Carelli V, et al. Matrices for site-specific controlled-delivery of 5-fluorouracil to descending colon. J Control Release. 2005;102:669-677.
21. Simeonova M, Velichkova R, Ivanova G, et al. Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. Int J Pharm. 2003;263:133-140.
22. Nair KL, Jagadeeshan S, Nair SA, Kumar GS. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomedicine. 2011;6:1685-1697.
23. Ma J, Chen CS, Blute T, Waxman DJ. Anti-angiogenesis enhances intratumoral drug retention. Cancer Res. 2011;71:2675-2685.
24. Banerjee S, Sen K, Pal TK, Guha SK. Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm. 2012;436:786-797.
25. Ragab DM, Rohani S, Consta S. Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates. Int J Nanomedicine. 2012;7:3167-3189.
26. Du JZ, Du XJ, Mao CQ, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc. 2011;133:17560-17563.
27. Ren X, Zheng N, Gao Y, Chen T, Lu W. Biodegradable three-dimension micro-device delivering 5-fluorouracil in tumor bearing mice. Drug Deliv. 2012;19:36-44.
28. Choi KY, Yoon HY, Kim JH, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011;5:8591-8599.
29. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer. 2010;46:1900-1909.
30. Yuan W, Liu Z. Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor. Int J Nanomedicine. 2011;6:3139-3149.
31. Xu L, Wu F, Yuan W, Jin T. Controlled-release implant system formulated using biodegradable hemostatic gauze as scaffold. Int J Pharm. 2008;355:249-258.
32. Diehl KH, Hull R, Morton D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21:15-23.
33. Konishi M, Tabata Y, Kariya M, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103:7-19.
34. Obara K, Ishihara M, Ozeki Y, et al. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Control Release. 2005;110:79-89.
35. Menei P, Boisdron-Celle M, Crousé A, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 1996;39:117-124.
36. Blanco MD, Sastre RL, Teijón C, Olmo R, Teijón JM. 5-Fluorouracil-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(lactide-co-glycolide) polymers: characterization and drug release. J Microencapsul. 2005;22:671-682.
37. Yuan W, Liu Z. Controlled release and preserved bioactivity of proteins from (self-assembled) core-shell double walled microspheres. Int J Nanome. 2012;7:257-270.
38. Rong X, Mo X, Ren T, et al. Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. Eur J Pharm Sci. 2011;43:334-342.
39. Ren T, Yuan W, Zhao H, Jin T. Sustained-release polylactidecoglycolide microspheres loaded with pre-formulated protein polysaccharide nanoparticles. Micro & Nano Letters, 2011;6(2):70-74.
40. Yuan W, Zhang Y, Wu F, et al. Jin T. Preparation of protein-loaded sustained-release microspheres via'solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/hO/E)' emulsification. Colloids Surf B, 2010; 79: 326-333.
41. Buckpitt AR, Boyd MR. A sensitive method for determination of 5-fluorouracil and 5-fluoro-2′-deoxyuridine in human plasma by high-pressure liquid chromatography. Anal Biochem. 1980;106:432-437.